-+ 0.00%
-+ 0.00%
-+ 0.00%

Ruanyun Edai signs deal to license Cogni AI platform exclusively to BioNexus Gene Lab in Malaysian healthcare

PUBT·10/05/2026 13:12:35
Listen to the news
Ruanyun Edai signs deal to license Cogni AI platform exclusively to BioNexus Gene Lab in Malaysian healthcare
  • Ruanyun Edai Technology signed a definitive deal to license its Cogni AI platform exclusively for Malaysian healthcare to BioNexus Gene Lab.
  • License runs 10 years from closing, renewable up to 20 years; RYET earns a 10% royalty on qualifying technology receipts.
  • BioNexus will issue 410,000 shares for the license, valued contractually at USD 3.5 million, settled in stock at closing.
  • Separate share exchange gives RYET 150,000 additional BioNexus shares for 500,000 new RYET ordinary shares; no cash consideration.
  • Closing is pending conditions; either side can walk if not closed by March 31, 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ruanyun Edai Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050900PRIMZONEFULLFEED9839531) on October 05, 2026, and is solely responsible for the information contained therein.